3 research outputs found

    Uncertainty reconciles complementarity with joint measurability

    Full text link
    The fundamental principles of complementarity and uncertainty are shown to be related to the possibility of joint unsharp measurements of pairs of noncommuting quantum observables. A new joint measurement scheme for complementary observables is proposed. The measured observables are represented as positive operator valued measures (POVMs), whose intrinsic fuzziness parameters are found to satisfy an intriguing pay-off relation reflecting the complementarity. At the same time, this relation represents an instance of a Heisenberg uncertainty relation for measurement imprecisions. A model-independent consideration show that this uncertainty relation is logically connected with the joint measurability of the POVMs in question.Comment: 4 pages, RevTeX. Title of previous version: "Complementarity and uncertainty - entangled in joint path-interference measurements". This new version focuses on the "measurement uncertainty relation" and its role, disentangling this issue from the special context of path interference duality. See also http://www.vjquantuminfo.org (October 2003

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
    corecore